Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

What this study is testing ClinicalTrials.gov NCT06657209 ↗

Description as written by the study sponsor.

This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.

Treatments tested

• Insulin resistance testing also known as SSPG Procedure

  Steady state Plasma Glucose test

• OGTT also known as Oral glucose tolerance test Procedure

  Will collect 5 blood draws during the test to measure insulin secretion

• Fat biopsy Procedure

  Needle biopsy to gather a sample of abdominal subcutaneous fat

• DXA scan Radiation

  Whole body DXA scan

• MRI Procedure

  Abdominal MRI

• 1H-MRS also known as proton magnetic resonance spectroscopy Procedure

  Spectroscopy of the abdominal region

• Tirzepatide also known as Mounjaro Drug

  16 weeks started at 2.5mg/week and increased to 5mg/week dose

• Pioglitazone also known as Actos Drug

  16 weeks at a 45mg/day dose